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Among candidate antigens for human immunodeficiency virus (HIV) prophylactic vaccines, the regulatory protein Tat is a critical early
target, but has a potential for immune suppression. Adenovirus (Ad) recombinants encoding wild-type HIV Tat (Tat-wt) and a transdominant
negative mutant HIV Tat (Tat22) were constructed and administered to mice separately or together with Ad-SIVgag. Immunogenicity and
effects on immune responses to the co-administered Gag immunogen were evaluated. Wild-type and mutant Tat recombinants elicited similar
Tat-specific cellular and humoral immune responses. Co-administration of either Tat immunogen with Ad-SIVgag induced modest but
significant enhancement of Gag-specific interferon-gamma secreting T cells and lymphoproliferative responses. Neither the Ad-recombinant
encoding Tat-wt nor Tat22 suppressed induction of anti-Tat or anti-Gag antibodies. Based on the immune responses observed in mice, both
recombinants appear to be suitable vaccine candidates. Their contribution to protective efficacy remains to be determined in a non-human
primate model.
Published by Elsevier Inc.Keywords: AIDS vaccine; HIV Tat; Adenovirus recombinantIntroduction
The difficulties in developing a vaccine against HIV/
AIDS have led to the realization that multi-component
immunogens eliciting both humoral and cellular immune
responses will be essential for achieving a successful vaccine
(Ho and Huang, 2002; Letvin et al., 2002; Malkevitch and
Robert-Guroff, 2004; McMichael and Rowland-Jones,
2001). Accumulating evidence from developmental HIV
and simian immunodeficiency virus (SIV) vaccine studies
indicates that vaccines encoding multiple viral antigens can0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2005.07.016
* Corresponding author. Fax: +1 301 496 8394.
E-mail address: guroffm@mail.nih.gov (M. Robert-Guroff).induce broader immune responses and/or greater protective
efficacy against viral infection (Hel et al., 2002; Kong et al.,
2003; Mossman et al., 2004; Negri et al., 2004; Ourmanov et
al., 2000; Patterson et al., 2004; Zhao et al., 2003b). In
addition to the viral structural and enzymatic proteins, Env,
Gag, and Pol, viral regulatory, and accessory proteins are
important potential vaccine components (Robert-Guroff,
2002). Tat, Rev, and Nef, in particular, have been targeted
by several laboratories for vaccine development (Cafaro et
al., 1999; Makitalo et al., 2004; Mossman et al., 2004;
Muthumani et al., 2002; Negri et al., 2004; Osterhaus et al.,
1999; Patterson et al., 2002; Richardson et al., 2002;
Tikhonov et al., 2003; Verrier et al., 2002).
Because of its critical role in viral pathogenesis and
infectivity (Chang et al., 1995), the transactivator protein,005) 1 – 12
J. Zhao et al. / Virology 342 (2005) 1–122Tat, has received much attention (Ensoli and Cafaro,
2000–01; Gallo, 1999; Goldstein, 1996). HIV-1 Tat is a
small nuclear protein, but it has a variety of activities. In
addition to functioning as a transcriptional transactivator of
HIV gene expression, Tat is released from productively
infected cells and can be taken up and imported into the
nucleus of many different cell types. There it promotes
HIV replication or modulates the expression of cellular
genes such as transcription factors, cytokines, and genes
that regulate the cell cycle and are important for HIV
replication (Barillari and Ensoli, 2002; Caputo et al.,
2004).
Extracellular Tat binds specific cell receptors and
phosphorylates tyrosine kinases, thus activating specific
signal transduction pathways, and upregulates the expres-
sion of the HIV co-receptors CCR5 and CXCR4
(Barillari and Ensoli, 2002; Caputo et al., 2004).
Extracellular Tat also has important effects on immuno-
regulatory functions (Caputo et al., 2004). In particular,
bioactive soluble Tat selectively binds to and enters
immature and mature dendritic cells (iDC and mDC,
respectively), drives iDC maturation and activation toward
a T helper 1 (Th-1) inducing phenotype (Fanales-Belasio et
al., 2002), facilitates major histocompatibility complex
(MHC) class I antigen presentation (Kim et al., 1997; Moy
et al., 1996), and modulates proteasome catalytic subunit
composition, modifying the hierarchy of epitopes presented
in favor of subdominant and cryptic ones (Gavioli et al.,
2004).
Extracellular Tat can also be immunosuppressive, and its
immune suppressive effects are thought to contribute to
AIDS pathogenesis (Gallo, 1999). Tat can induce apoptosis
in T cells by a process involving activation of cellular cyclin
dependent kinases (Li et al., 1995). Tat has been shown to
upregulate Fas L on macrophages (Dockrell et al., 1998; Wu
and Schlossman, 1997) and T cells (Kolesnitchenko et al.,
1997), resulting in apoptosis of Fas expressing T cells. A
critical report demonstrated that in mice native Tat
immunization in complete Freund’s adjuvant suppressed
the induced antibody response to a co-administered antigen,
and that this was abrogated by oxidation of the Tat molecule
(Cohen et al., 1999).
Because it is produced early in the HIV replication
cycle, vaccine-induced immune responses to Tat might
inhibit Tat functions, abrogating both HIV transactivation
and the deleterious effects of Tat on uninfected, bystander
cells, as well as target early HIV infected cells. However,
the potential use of Tat as a vaccine candidate is
controversial. On the positive side, studies of HIV-infected
patients and SIV-infected non-human primates suggest that
an immune response to Tat has a protective role and may
control the progression of the disease. Anti-Tat antibody
responses and CTLs have been associated with non-
progression to AIDS in infected individuals (Re et al.,
2001; Reiss et al., 1990; van Baalen et al., 1997; Zagury et
al., 1998; Rezza et al., 2005). Furthermore, a recent studyin macaques infected with SIV demonstrated that anti-Tat
CTLs are key to control of early virus replication (Allen et
al., 2000). As a vaccine candidate, however, mixed results
have been obtained using different approaches. Immuniza-
tion with active Tat protein has led to strong protection of
cynomolgus macaques in pre-clinical vaccine studies
against intravenous challenge with SHIV89.6P (Cafaro et
al., 1999; Maggiorella et al., 2004). In contrast, immuni-
zation with either inactivated or native Tat has shown
minimal or no protection of rhesus macaques against
intrarectal (Pauza et al., 2000) or intravenous (Silvera et
al., 2002) SHIV89.6P challenge, intrarectal SHIVBX08
challenge (Verrier et al., 2002), or intravenous SHIV33 or
SHIV33A challenge (Goldstein et al., 2000). Whether
these mixed outcomes reflect species differences, route or
strain of challenge, or differences in the Tat immunogens
or vaccine regimens is not clear. Taken together, these
observations suggest that additional investigation of HIV-1
Tat vaccines is warranted.
The present study was undertaken to investigate the
vaccine potential of a replicating Ad recombinant encoding
HIV-1 Tat, a vaccine design aimed at inducing a more potent
cellular immune response than would be expected for
protein alone or DNA-based vaccines. We compared Ad-
recombinants encoding both native Tat and a Tat mutant
(tat22; Cys 22 to Gly) lacking transactivation ability
(Caputo et al., 1996). Previously, intramuscular immuniza-
tion of mice with plasmids encoding transdominant negative
mutants of HIV-1 Tat, including Tat22, was shown to elicit a
humoral response to wild-type Tat comparable to that
induced by inoculation of wild-type tat DNA (Caselli et
al., 1999). Here, we compared the immunogenicity of the
two candidate vaccines and examined their effects on the
immune response to a co-administered Ad-recombinant
vaccine encoding SIV Gag.Results
Construction of Ad-recombinants encoding wild-type and
mutant tat genes
Ad type 5 host range mutant (Ad5hr)-recombinants
containing the full-length cDNA of the HIV-1 wild-type
tat gene (Ad5hr-HIVtat-wt) or the Tat transdominant
negative mutant (Ad5hr-HIVtat22) under the transcriptional
control of a hybrid gene regulation unit, consisting of a
human CMV promoter followed by the Ad5 tripartite leader
sequence, were constructed as described in Materials and
methods. The Ad5hr vector was used to facilitate future
efficacy studies in the rhesus macaque model by allowing
replication of the Ad-recombinant. Western blot analysis
showed the levels of in vitro expression of the wild-type and
mutant tat genes were comparable following infection of
human 293 cells with the Ad5hr-recombinants (data not
shown).
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Ad5hr-recombinants replicate in monkeys, whereas in
mice, the inserted genes are expressed, but recombinant
replication does not occur. Here, we assessed the immuno-
genicity of the recombinants in Balb/C mice prior to future
testing in the SIV rhesus macaque challenge model. The
protocol is outlined in Table 1 and detailed in Materials and
methods. We immunized 10 mice each in groups I and II with
an Ad5hr-recombinant encoding wild-type or mutant tat,
respectively. Because of previous reports concerning sup-
pression of antibody responses to other antigens co-admin-
istered with native Tat protein, we included immunization
groups III–V, in which 10mice each received Ad5hr-SIVgag
alone or together with Ad5hr-HIVtat-wt or Ad5hr-HIVtat22.
A sixth control group received empty Ad5hrDE3 vector only.
Two additional groups (VII and VIII) were included to
examine a possible immune modulating effect of prior
immunity to wild-type or mutant Tat by administering first
Ad5hr-HIVtat-wt or Ad5hr-HIVtat22 alone and subse-
quently 4 weeks later, Ad5hr-SIVgag together with Ad5hr-
HIVtat-wt or Ad5hr-HIVtat22. Immune responses were
evaluated in these mice at week 6.
Antigen-specific cellular immune responses
An IFN-g ELISPOT assay was used to assess Tat- and
Gag-specific cellular immune responses elicited by the
Ad5hr-recombinant vaccines. Ad5hr-recombinants encod-
ing Tat-wt and Tat22 were equally immunogenic, with no
differences observed in the number of Tat-specific IFN-g-
secreting spot-forming cells (SFC) between groups I and II
following either the first or second immunizations (Fig.
1A). Similarly, the Tat-specific ELISPOT responses seen at
both time points in Groups IV and V in which Ad5hr-
SIVgag was co-administered were also equivalent. In all
cases, except for Group II mice immunized with Ad5hr-
HIVtat22, a second immunization with the same Ad5hr-
recombinant significantly boosted the Tat-specific cellularTable 1
Mouse immunization schedule
Group Immunogens # Mi
immu
week
I Ad5hrDE3-HIVtat-wt 10
II Ad5hrDE3-HIVtat22 10
III Ad5hrDE3-SIVgag 10
IV Ad5hrDE3-HIVtat-wt + Ad5hrDE3-SIVgag 10
V Ad5hrDE3-HIVtat22 + Ad5hrDE3-SIVgag 10
VI Ad5hrDE3 vector 10
VIIa Ad5hrDE3-HIVtat-wt 5
Ad5hrDE3-HIVtat-wt + Ad5hrDE3-SIVgag 0
VIIIa Ad5hrDE3-HIVtat22 5
Ad5hrDE3-HIVtat22 + Ad5hrDE3-SIVgag 0
a In groups VII and VIII, 5 mice each were first immunized at week 0 with Ad5h
boosted at week 4 with the same recombinants together with Ad5hrDE3-SIVgagresponse (P = 0.028, 0.071, 0.0031, and 0.023 for Groups
I, II, IV, and V, respectively; Fig. 1A). A small but
significant decrease in the number of IFN-g-secreting cells
in response to Tat peptides was seen in mice co-immunized
with the Ad5hr-SIVgag recombinant and either Ad5hr-
HIVtat-wt or -HIVtat22 following the second immuniza-
tion (Group I vs. IV, P = 0.0096; Group II vs. V, P =
0.0072; Fig. 1B). Whether these minimal decreases of 20
mean SFC (10% decrease) for Ad5hr-HIVtat-wt and 41
mean SFC (19% decrease) for Ad5hr-HIVtat22 in the
overall induced cellular response to Tat would be repro-
duced in primate models and affect protective efficacy will
need to be evaluated in future studies.
As previously seen in the macaque model (Zhao et al.,
2003a), the Ad5hr-SIVgag recombinant was also immuno-
genic in mice. A boosting effect of two sequential
immunizations was seen in the Gag cellular immune
response in all three groups that received this Ad5hr-
recombinant (P < 0.0001, P = 0.0094, P < 0.0001 for
Groups III, IV, and V, respectively; Fig. 1A). In contrast to
the small decrease in cellular immune response to Tat seen
upon co-administration of the Ad5hr-SIVgag recombinant,
both the Ad5hr-HIVtat-wt and -HIVtat22 co-administra-
tions had an enhancing effect on cellular responses to Gag.
The number of Gag-specific IFN-g-secreting cells seen
following both the first and second immunizations was
significantly increased (Group III vs. IV, P = 0.0001 and
P = 0.015 post-first and -second immunization; Group III
vs. V, P = 0.0012 and P < 0.0001 post-first and -second
immunization; Fig. 1B). The increases in the Gag-specific
responses observed 2 weeks after the first immunizations
were 116 mean SFC (46%) and 78 mean SFC (31%) for
mice co-immunized with the Ad5hr-HIVtat-wt and Ad5hr-
HIVtat22 recombinant immunogens, respectively, and 240
mean SFC (59%) and 172 mean SFC (42%) respectively at
week 6 following the second immunization. These results
indicate that rather than suppressing cellular immunity,
both wild-type and mutant Tat immunogens administered
as Ad-recombinants can enhance the cellular immunece
nized
0
# Mice
sacrificed
week 2
# Mice
immunized
week 4
# Mice
sacrificed
week 6
5 5 5
5 5 5
5 5 5
5 5 5
5 5 5
5 5 5
0
5 5
0
5 5
rDE3-HIVtat-wt or Ad5hrDE3-HIVtat22. The same mice were subsequently
, and sacrificed at week 6.
Fig. 1. IFN-g ELISPOT responses to HIV-1 Tat and SIV Gag peptides following each Ad-recombinant immunization. Freshly isolated splenocytes were assessed
for IFN-g ELISPOT responses after in vitro exposure to peptide pools spanning the HIV-1IIIB Tat and SIVmac239 Gag proteins. Spot forming cells (SFC) are
reported following subtraction of background spots observed in the presence of medium alone. Data are presented as mean SFC T standard errors of the means.
Panels A and B present identical data in order to illustrate statistically significant differences between immunization groups. Statistical analyses were performed
by first testing for homogeneity of variance in the responses for the two groups being compared. For groups with homogeneous variances, t tests were used. For
groups with non-homogeneous variances, a Welch modified t test was employed, indicated by an asterisk. NS = not significant.
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specific cellular responses were slightly higher following
one co-administration with Ad5hr-HIVtat-wt compared to
Ad5hr-HIVtat22 (Group IV vs. V, post-first, P = 0.014),
this difference disappeared following the second co-administrations (Group IV vs. V, post-second, P = 0.20)
as shown in Fig. 1B. Thus, overall, both the wild-type and
mutant Tat immunogens exerted a similar enhancing effect
on the immune response of the co-administered SIV Gag
immunogen.
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immunity observed in the co-immunization groups, we
looked for immune modulation of cellular immune
responses to the Ad5hr-vector itself, by evaluating IFN-g
secretion in response to the Ad5 fiber protein. No differ-
ences in ELISPOT responses to Ad5 fiber peptides were
seen among any of the immunization groups. Mean Ad5
fiber-specific responses in Groups I through VI at week 2
ranged from 167 to 186 SFC/106 splenocytes and at week 6
from 175 to 239 SFC/106 splenocytes.
T cell proliferation assays were conducted to determine if
the vaccine-induced cellular immune responses detected by
ELISPOT assay were mirrored by responses to intact Tat
protein and SIV p27. Proliferative responses to native and
oxidized Tat protein were equivalent (data not shown).
Therefore, only results with the oxidized protein are
presented. Similar to results obtained for IFN-g secretion,
no difference was observed in the ability of Ad5hr-HIVtat-
wt or -HIVtat22 to elicit potent Tat-specific T cell
proliferative responses. The mean SI in response to Tat
protein (Fig. 2) was similar following each immunization
regardless of whether mice received a single Ad-recombi-
nant encoding native or mutant Tat (Groups I and II), or
were co-immunized with Ad5hr-SIVgag (Groups IVand V).
A boosting of the Tat-proliferative response by a second
recombinant administration was detected in immunization
groups I and II (P = 0.0001 and 0.0003, respectively), and
in groups IVand V that received the co-administered Ad5hr-
SIVgag (P = 0.0030 and 0.0002, respectively). No
proliferative responses to Tat above background levels were
observed in Group VI mice that received only the Ad5hr-
vector, indicating not only the specificity of the Tat-response
in the immunized mice, but also the absence of non-specificFig. 2. Lymphoproliferative responses to oxidized HIV-1 Tat and SIV Gag antigens
were assessed for T cell proliferative activity to Tat and Gag p27 proteins as de
indices T standard errors of the means. All statistical analyses were performed bystimulation in vitro by the Tat protein preparation. A single
administration of Ad5hr-SIVgag recombinant was sufficient
to elicit a potent Gag-specific proliferative response that was
not significantly boosted by the second administration. We
speculate that the immunization regimen was too com-
pressed to allow optimal boosting of this induced immune
response.
As with cellular responses evaluated for SIV-specific
IFN-g-secreting cells, the SI in response to p27 Gag was
also enhanced by co-administration of Ad5hr-recombinants
encoding either Tat-wt or Tat22 (Fig. 2). Significant
enhancement in the Gag proliferative response of 37%
resulted from co-administration of the Ad5hr-HIVtat-wt
recombinant after the week 0 immunizations (Group III vs.
IV; P = 0.037; Fig. 2). Following the week 4 booster
immunizations, the Gag proliferative responses in mice co-
administered the Tat-wt recombinant also increased (36%)
compared to mice that received the Gag recombinant
alone, but in this case, statistical significance was not
reached (P = 0.079). Co-administration of the Tat22 and
Gag recombinants resulted in significant increases in the T
cell proliferative response to p27 of 49% after both the
first and second administrations (Group III vs. V; P =
0.010 and 0.029, respectively; Fig. 2). Thus, the overall
evaluations of immunity induced by the vaccination
regimen indicated enhanced cellular immune responses to
SIV Gag resulted from co-administration of the Ad-tat
recombinant immunogens.
Humoral immune responses
Having shown that both the Ad5hr-HIVtat-wt and
-HIVtat22 vaccines were immunogenic and able to elicitfollowing each Ad-recombinant immunization. Freshly isolated splenocytes
scribed in Materials and methods. Data are presented as mean stimulation
t test, as groups being compared had homogeneous variances.
Table 2
Antibody responses to Tat and Gag post-second immunization
Statistical analyses were performed by t test, as variances between groups were homogeneous. NS = not significant. The single statistically significant
difference is indicated in bold.
Table 3
Effect of prior immunization with Ad-recombinants encoding Tat-WT or
Tat22 on cellular response to co-administered Ad-recombinant encoding
SIV Gag
Mean values T standard error of the mean reported. *Statistical analysis
performed by Welch’s modified t test. All other analyses were by t test.
NS = not significant.
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immunity elicited by the vaccines. While enhanced cellular
immunity to a co-administered antigen was demonstrated
above, previous reports have shown suppression of antibody
responses to a co-administered antigen in the presence of
active Tat protein (Cohen et al., 1999). Antibody titers
induced following immunization with the Ad5hr-recombi-
nants were relatively low overall.
However, 2 weeks after the second Ad-recombinant
immunizations, antibody responses to Tat and SIV p27 were
detected in the appropriate immunization groups (Table 2).
Anti-Tat titers elicited by the Ad5hr-HIVtat-wt and Ad5hr-
HIVtat22 immunizations were similar regardless of whether
they were administered singly or together with the Ad5hr-
SIVgag recombinant. No significant differences in Tat
antibody titers were seen between groups I and II and IV
and V. Further, unlike the immune modulation seen in the
cellular immune responses, no significant increase or
decrease was observed in either anti-Tat or anti-Gag
antibody titers upon co-administration of Ad5hr-HIVtat-wt
or -HIVtat22 with Ad5hr-SIVgag (compare groups I vs. IV
and II vs. V for Tat antibodies; groups III vs. IVand III vs. V
for Gag antibodies; Table 2). Overall, however, mice co-
administered Ad5hr-HIVtat-wt and Ad5hr-SIVgag
exhibited somewhat greater anti-Gag titers compared to
mice co-administered Ad5hr-HIVtat22 and Ad5hr-SIVgag
(P = 0.030). Mice in this same immunization group had also
exhibited greater IFN-g secretion in response to Gag
peptides compared to mice co-immunized with Ad5hr-
HIVtat22 and Ad5hr-SIVgag, significantly increased after
the first immunization but not after the second (Fig. 1B),
suggesting a possible advantage of the Tat-wt immunogen.
This observation should be further evaluated in a primate
model.Ad5 neutralizing antibody titers were determined on
mouse sera from all groups, and similar to results of
ELISPOT assays for Ad5 fiber peptides, no significant
differences were observed among the immunization groups.
Effect of prior Tat immunization on elicitation of immune
responses to Gag
To evaluate the effect of prior Tat immunization on
elicitation of immune responses to Gag, two immunization
groups were studied in which mice were first immunized
with Ad5hr-HIVtat-wt (Group VII) or Ad5hr-HIVtat22
(group VIII) alone, and then were co-administered the
HIVtat-wt or HIVtat22 recombinant together with Ad5hr-
SIVgag at week 4. Following the co-administration, cellular
and humoral immune responses to Gag were compared at
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tration (week 2) in groups IV (Ad5hr-HIVtat-wt plus
Ad5hr-SIVgag) and V (Ad5hr-HIVtat22 plus Ad5hr-SIV-
gag). The results are shown in Table 3. There were no
significant differences in Gag-specific IFN-g secretion
between groups with regard to prior Tat exposure. In
addition, proliferative responses to p27 were not signifi-
cantly decreased by prior immunization with Ad5hr-HIVtat-
wt. However, there was a marginally significant decrease in
the proliferative response to Gag following prior immuni-
zation with Ad5hr-HIVtat22 (P = 0.045), again suggesting
a possible benefit of using the Tat-wt immunogen. In
general, two immunizations with the Ad5hr-SIVgag
recombinant were needed for induction of a Gag-specific
antibody response, so no prior effect of anti-Tat immunity
on Gag antibody responses was observed in groups VII and
VIII in which mice received only a single Ad5hr-SIVgag
immunization.Discussion
In the present study, we have demonstrated that both
Tat-wt and the mutant Tat22, administered as Ad5hr-
recombinants, are highly immunogenic in Balb/C mice.
Cellular immune responses, including secretion of IFN-g
in response to Tat peptides and T cell proliferative
responses to both native and oxidized Tat protein, were
readily detected after a single immunization and were
efficiently boosted by a second immunization with the
same recombinant. Our immunization strategy using Ad
vectored vaccines is aimed at eliciting cellular immunity
and priming humoral immune responses. In keeping with
this, as the experimental protocol did not include booster
immunizations with Tat protein, antibody responses to Tat
required two Ad-recombinant administrations for induction
and overall were modest.
Not only were the Ad5hr-HIVtat-wt and -HIVtat22
recombinants immunogenic in mice, stimulating strong
cellular responses to Tat, they also enhanced cellular
immune responses to SIV Gag, co-administered as an
Ad5hr-SIVgag recombinant. Modest enhancement of both
Gag-specific IFN-g secretion and T cell proliferation was
observed. This is in apparent contrast to previous reports
showing immune suppressive effects of Tat (Cohen et al.,
1999; Dockrell et al., 1998; Kolesnitchenko et al., 1997; Li
et al., 1995; Wu and Schlossman, 1997). However, there is
an increasing body of evidence suggesting that the
immunomodulatory activities of Tat are immunostimulating
rather than immunosuppressive. In fact, recent data indicate
that Tat in its native form selectively binds to and is taken up
by DC in which it induces activation and maturation into
mDC (Fanales-Belasio et al., 2002). In particular, DC
exposed to Tat upregulate key co-stimulatory molecules
such as CD40, CD80, CD86, LFA-1, MHC Class I and II
antigens, and produce inflammatory (TNF-a) and Th-1-polarizing (IL-12) cytokines and h-chemokines (RANTES,
MIP-1a, and MIP-1h). Of importance, in vitro responses to
allo and recall antigens are also increased (Fanales-Belasio
et al., 2002).
Tat contains a cationic region, amino acids 48–60,
identical in both the Tat-wt and Tat22 immunogens tested
here, that increases expression of epitope/MHC class I
complexes on the cell surface (Leifert et al., 2003; Lindgren
et al., 2000). However, this mechanism would not have
influenced immunity to SIV Gag, administered as a separate
Ad5hr-recombinant. Therefore, the most likely explanation
for the observed enhanced cellular immunity to Gag is an
upregulation of inflammatory and immunostimulating cyto-
kines and chemokines attributable to Tat expression
(Izmailova et al., 2003), leading to an overall cellular
immune enhancement. An alternative explanation, however,
is a general effect attributable to immunization with a
mixture of antigens. We have previously reported immune
modulatory effects in rhesus macaques immunized with
Ad5hr-SIV recombinants encoding SIV env/rev, gag, and/or
nef (Patterson et al., 2003). The cellular immune response to
Env was significantly enhanced in monkeys that received
both Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants,
while the cellular immune response to Nef was decreased in
monkeys immunized with Ad5hr-SIVenv/rev, Ad5hr-SIV-
gag, and Ad5hr-SIVnef. Importantly, this immune modu-
lation was only observed during the period of Ad-
recombinant priming, and disappeared with time over the
course of the immunization regimen during the period of
protein boosting. Further, the initial immune modulation had
no effect on vaccine-induced protection, as similar protec-
tive efficacy was observed among the macaque groups that
received the multigenic Ad-recombinants following chal-
lenge with SIVmac251 (Patterson et al., 2004). The
generality of Tat-induced enhancement of cellular immunity
when administered as an Ad-recombinant and the eventual
effect of any modulation on vaccine efficacy should be
further evaluated in macaques which allow both replication
of the Ad-recombinant immunogens and challenge with an
appropriate SHIV isolate.
Extracellular Tat has been shown to inhibit proliferation
of naı¨ve and memory B cells triggered via the B cell
receptor (Lefevre et al., 1999). This may explain the
previously observed inhibition of anti-Tat and anti-Gag
antibody responses following co-administration of native,
but not oxidized, Tat with Gag protein immunogens
(Cohen et al., 1999). Elicitation of a potent anti-Tat
antibody response appears to be a desirable feature for
an effective HIV/AIDS vaccine, in order to inhibit early
effects of extracellular Tat released from infected cells. In
fact, a correlation between the presence of anti-Tat
antibodies and delayed progression to disease has been
reported (Butto et al., 2003; Rezza et al., 2005). To
achieve this, in combination with our Ad-recombinant
priming strategy, boosting with Tat protein would likely be
necessary. The induction of high-titered antibodies to HIV
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lowed by boosting with subunit proteins has been well
documented (Buge et al., 1997; Lubeck et al., 1997).
Similarly, priming of monkeys with DNA plasmids
encoding Tat followed by boosting with Tat-protein
together with ISCOM adjuvant has elicited strong anti-
Tat responses (Mooij et al., 2004). Recent data suggest that
most of the anti-Tat antibodies induced during natural
infection are conformational, since major differences were
observed when linear Tat peptides or oxidized Tat protein
were used instead of the native Tat protein to detect
specific antibodies (Butto et al., 2003). Further, a
substantial cross-recognition of HIV-1 clade B Tat by sera
from Ugandan and South African individuals infected
mainly with HIV-1 from subtypes A, C, and D was found,
indicating that both linear and conformational B cell
epitopes are relatively well-conserved across different
clades (Butto et al., 2003). Others have also reported
significant serologic cross-clade Tat reactivity (Goldstein et
al., 2001; Ruckwardt et al., 2004). Taken together, these
data suggest that booster immunizations with native
Tat protein rather than the oxidized form or peptides
would be preferred. In contrast, cellular immunity to Tat
was elicited to a similar extent by both Ad5hr-HIVtat-wt
and -HIVtat22, suggesting that use of either immunogen
would be suitable for priming. Whether immune modu-
lation mediated by native Tat protein might lead to
suppression of antibody responses following strong pri-
ming by the Ad-recombinants encoding Tat-wt or Tat22
remains to be determined.
Since the regulatory protein Tat plays a critical role in
viral pathogenesis and infectivity, a Tat-based vaccine might
achieve substantial control of infection by targeting extrac-
ellular Tat with specific antibodies and newly infected cells
with anti-Tat CTLs. With this rationale, preventive and
therapeutic phase I trials with the native Tat protein are
ongoing in Italy. Nevertheless, the immunoregulatory and
adjuvant functions of Tat (Fanales-Belasio et al., 2002;
Gavioli et al., 2004) suggest that an AIDS vaccine
combining Tat with other relevant antigens might be
superior to vaccines based on single components (Mooij
et al., 2004). In this regard, our observation that Tat,
administered as an Ad-recombinant, enhances cellular
immune responses to a co-administered immunogen in
mice is important and relevant to vaccine design, and should
be confirmed in primates. We have previously shown
significant protective efficacy against the highly pathogenic
SIVmac251 strain, achieved by priming with multigenic
Ad5hr-SIV recombinants and boosting with envelope
subunits (Patterson et al., 2004). The present results suggest
that the incorporation of Tat into a similar vaccine strategy
might enhance cellular immune responses elicited by other
Ad-recombinants and at the same time elicit Tat-specific
immunity, of potentially great value in targeting an HIV
antigen that is expressed very early after HIV entry, even
before virus integration (Wu and Marsh, 2001).Materials and methods
Adenovirus type 5 host range (Ad5hr) recombinants
A replication competent Ad5hr-SIV recombinant carry-
ing the SIVmac239 gag gene was described previously (Zhao
et al., 2003a). Plasmids pBRAdDE3 and pAd5tpl5-18RD2
used for construction of Ad5hr-HIVtat-wt and Ad5hr-
HIVtat22 recombinants were obtained from Wyeth-Lederle
Vaccines under a Cooperative Research and Development
Agreement. pBRAdDE3 contains the Ad5 sequence from
59.5 to 100 map units (mu) in which the E3 region from
78.8 to 85.7 mu is deleted. Plasmid pCI vector containing
CMV and polyA was purchased from Promega (Madison,
WI). Ad5hr-recombinants carrying HIVtat-wt and the
transdominant mutant tat22 (Cys22 to Gly) (Caputo et
al., 1996) were constructed as follows. First, the CMV
promoter, the tpl of the Ad5 serotype (tpl5), tat-wt (or
tat22), and polyA were amplified separately by PCR with
four pairs of primers: CMV5 p1 (5V to 3V): CCTCTAGTTA-
TAGTAATCAATTACGGGGTCATT and tpl5-CMV-R
CGGAAGAGAGTCGAGCTCTGCTTAT; CMV-tpl5-F:
GCAGAGCTCGACTCTCTTCCGCATCGC; and tat-tpl5-
R: CTACAGGCTCCATCTTGCGACTGTGAC; tpl5-tat-F
GTCACAGTCGCAAGATGGAGCCAGTAG and Tat-
polyA-F: CCGAAGGAATAGTGATCCCCCGAC; and
Tat-polyA-R: TCGGGGGATCACTATTCCTTCGG and
CMV5p2 CCTCTAGATCTCCGAGGGATCTCGAC-
CAAAT. Secondly, a hybrid expression cassette of CMV-
Ad5tpl-Tat-wt (or Tat22)-polyA was assembled by PCR
using a mixture of the above PCR products as template
and the primer pair CMV5 p1 and CMV5 p2. The ampli-
fied expression cassette was then inserted into the Xba1
site at 78.8 mu of pBRAdDE3. The correct gene orienta-
tion and sequence of both pBRAdDE3HIVtat-wt and
pBRAdDE3HIVtat22 were confirmed by DNA sequencing.
The Ad5hr-HIVtat-wt recombinant was generated by
homologous recombination between Ad5hr viral DNA,
1 to 76 mu, and pBRAdDE3HIVtat-wt as described
previously (Zhao et al., 2003a). The Ad5hr-HIVtat22
recombinant was similarly constructed by homologous
recombination between Ad5hr viral DNA, 1 to 76 mu,
and pBRAdDE3HIVtat22.
Expression of the Tat protein in human 293 cells infected
with the Ad5hr-HIVtat-wt or HIVtat22 recombinant was
evaluated by Western blot. The 293 cells were infected at an
MOI of 10 with the recombinants or the Ad5hrDE3 vector
as negative control. When 90% of the cells exhibited a
cytopathic effect, cell lysates were prepared with radio-
immunoprecipitation assay buffer (50 mM Tris–HCl, pH
8.0, containing 150 mM NaCl, 1% polyethoxyethanol
(Sigma, St. Louis, MO), 0.5% sodium deoxycholate, 0.1%
sodium dodecyl sulfate (SDS), and 1 mM phenylmethyl-
sulfonyl fluoride), separated on an SDS-polyacrylamide
gradient gel of 4–20% (Bio-Rad), and then transferred onto
a nitrocellulose membrane (Bio-Rad). Tat expression was
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Tat monoclonal antibody (NT3 2D1.1; AIDS Research and
Reference Reagent Program, NIAID, NIH) and subse-
quently visualizing bands using the ECL Western blotting
detection reagent (Amersham Pharmacia Biotech, Piscat-
away, NJ), as described by the manufacturer.
Immunization of mice and sample collection
Female Balb/C mice at 6–8 weeks of age were used in
this study. Each group included 10 mice except groups VII
and VIII that contained 5 mice each. The immunization
schedule is outlined in Table 1. Each Ad-recombinant was
administered intraperitoneally at 108 plaque-forming units
(pfu) per immunization in a total volume of 500 Al
phosphate-buffered saline (PBS) regardless of the number
of recombinants given. Five mice per group in groups I–VI
were sacrificed 2 weeks after the first immunization and 5
mice per group in groups I–VIII were sacrificed 2 weeks
after the second immunization at week 4. Spleens and blood
were collected to evaluate immune responses. Mouse
splenocytes were isolated by passing spleen fragments
through a 70 Am nylon cell strainer. After lysis of
erythrocytes, the splenocytes were resuspended in R-10
medium (RPMI-1640 containing 10% FCS, 2 mM l-
glutamine, 25 mM HEPES, 100 U/ml penicillin, and 100
Ag/ml streptomycin).
ELISPOT assay
IFN-g secretion in response to SIV Gag, HIV-1 Tat, and
Ad5 fiber peptides was evaluated by ELISPOT assay. Gag
peptides included 50 20-mer peptides with 10-amino acid
overlap, spanning the entire SIVmac239 Gag protein. HIV-
1 Clade B consensus Tat peptides included 23 15-mer
peptides with 11-amino acid overlap. Both SIV Gag and
HIV-1 Tat peptides were obtained from the AIDS Research
and Reference Reagent Program, NIAID, NIH. The Ad5
fiber peptides consisting of 142 15-mers overlapping by 11
amino acids were obtained from Advanced BioScience
Laboratories, Inc. (ABL, Kensington, MD). The ELISPOT
assay for the Th-1 cytokine IFN-g was performed using
commercial kits (U-Cytech, Utrecht, The Netherlands)
according to the manufacturer’s manual with slight
modification. Briefly, 96-well flat-bottom plates were
coated overnight with anti-IFN-g monoclonal antibody
MD-1 (U-Cytech), washed and blocked as described.
Dilutions of splenocytes ranging from 2  105 to 0.25 
105 per 100 Al R-10 medium were transferred to triplicate
wells, together with 2 Ag/ml of each peptide in the Gag,
Tat, or Ad5 fiber peptide pools. The Tat peptides were used
as a single pool. Responses to Gag and the Ad5 fiber were
evaluated using 2 pools of Gag peptides (25 each) and 2
pools of Ad5 fiber peptides (71 each). Following sub-
traction of background spots, values for the Gag and Ad5
fiber pools were summed. Concanavalin A (Con A)(Sigma) at 5 Ag/ml and R-10 medium alone were used as
positive and negative controls. Following overnight incu-
bation at 37 -C in 5% CO2, the cells were removed, and the
wells washed and incubated with biotinylated anti-IFN-g
antibody (U-Cytech). After further washing, bound anti-
IFN-g antibody was detected with a gold-labeled anti-biotin
solution (U-Cytech). Spots were developed by incubating
the plates with U-Cytech’s activator mixture. The color
reaction was stopped by washing with distilled water. The
plates were air-dried, and spots were counted visually using
an inverted microscope.
T cell proliferation
To account for possible effects of native Tat protein on
splenocytes during the period of in vitro stimulation, both
native and inactivated Tat proteins were evaluated in
proliferative assays. Biologically active Tat protein (ABL),
greater than 95% pure, was purified as previously described
(Chang et al., 1997) followed by reverse phase HPLC to
remove LPS. Assay for endotoxin showed 0.45 EU/Ag Tat.
Since Tat is easily oxidized and photo- and thermo-
sensitive, the native Tat protein was reconstituted in
degassed PBS containing 0.1% bovine serum albumin
(BSA) immediately prior to use, and the handling of the
protein was performed in the dark and on ice. Oxidized Tat
protein was prepared by exposing the active Tat protein to
air and light for 24 h. Cells were cultured in triplicate, at 2 
105/well in 200 Al R-10 in the presence of active Tat or
oxidized Tat proteins (5 Ag/ml), or SIV p27 (2 Ag/ml)
(ABL). Con A (5 Ag/ml) and R-10 medium alone served as
positive and negative controls, respectively. Following 5
days incubation at 37 -C in 5% CO2, the cells were pulsed
with [3H]thymidine (1 ACi per well) and further incubated
overnight. Cells were harvested using a Mach IIM (Tomtech
Inc.) cell harvester and counted on a Pharmacia (Wallac
Inc.) beta-plate counter. Stimulation indices (SI) were
calculated by dividing the mean counts per minute (cpm)
with antigen by the mean cpm with medium alone.
Serological responses
Anti-Ad5 neutralization titers were determined by micro-
titer-neutralization assays on A549 cells as described
previously (Chengalvala et al., 1991), using serial two-fold
dilutions of mouse sera. Endpoint titers were defined as the
reciprocal of the last serum dilution at which an Ad5
cytopathic effect was not observed.
Serum antibodies to SIV Gag were assayed by enzyme-
linked immunosorbent assay (ELISA) using 25 ng of SIV
p27 per microtiter well and horse radish peroxidase-
conjugated goat anti-mouse IgG (1:25000). All sera were
initially tested at a 1:50 dilution and then titered to endpoint
as needed. The binding titer was defined as the reciprocal of
the serum dilution at which the absorbance of the test serum
was twice that of the negative control serum diluted 1:50.
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Nunc-Immuno MaxiSorp 96-well plates were coated with
Tat protein (100 ng/well in 0.05 M carbonate buffer, pH 9.6)
for 12 h at 4 -C, washed 5 times with PBS without Ca2+ and
Mg2+ containing 0.05% Tween 20 (PBS/Tween), and
blocked with PBS containing 1% BSA and 0.05% Tween
20 (blocking buffer, BB) for 90 min at 37 -C. After
extensive washings, aliquots of mouse sera, serially diluted
in BB beginning at 1:100, were added to duplicate wells.
Sera were also tested against wells coated with the buffer in
which Tat had been resuspended to correct for any non-
specific binding. After a 90-min incubation at 37 -C, the
plates were washed extensively, and the wells were
saturated with BB for 15 min at 37 -C. After further
washing, 100 Al of horseradish peroxidase-conjugated anti-
mouse IgG (Sigma) diluted 1:1000 in BB was added to each
well. The plates were incubated an additional 90 min at
37 -C, washed, and developed with ABTS substrate solution
(Roche Diagnostics) for 50 min at 37 -C. Absorbance was
measured at 405 nm using a Sorin Biomedica microplate
reader. Optical densities (OD) of the samples were
normalized against the buffer-coated wells for each sample.
The difference (D) in OD between the Tat and buffer coated
wells was calculated. Positive and negative controls
included one known Tat-antibody positive sample and 3
known Tat-antibody negative samples. The assay was
considered valid if the both the D values and the absolute
OD values of the positive and negative controls prior to
normalization were within 10% of the values observed in 50
previous assays. A positive sample was defined as 3
standard deviations above the mean of both absolute OD
and D values obtained from 50 assays of Tat antibody
negative mouse sera. Antibody titer was defined as the
reciprocal of the serum dilution at which the mouse serum
still gave a positive value.
Statistical methods
Data in this study were analyzed using standard para-
metric and non-parametric methods, meaningful descriptive
and graphical techniques, and followed up with standard
post hoc parametric tests (e.g., Tukey’s HSD method) and
non-parametric tests (e.g., Wilcoxon). As our results
satisfied normality and homogeneity of variance assump-
tions, and as all post hoc results were in agreement,
interpretively, with results obtained from t tests, we report
probability values from t tests (or Welch’s modified t test) as
appropriate. All tests were two-sided; probability values less
than 0.05 were considered significant.Acknowledgments
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